Literature DB >> 3961427

Epidemiology of schizophrenia: a European perspective.

A Jablensky.   

Abstract

Since its inception, the concept of dementia praecox and, later, of schizophrenia has been one of the most disputed entities in modern medicine. Schizophrenia was, and still is, defined by its clinical symptoms and their characteristic evolution over time. No external validating criteria for the diagnosis have been established, in spite of a host of suggestive biological findings, among which the genetic data carry most weight. This absence of clear-cut substrate markers and indicators underscores the importance of the epidemiological perspective in the study of the disorder. The European contributions to the epidemiological description and understanding of schizophrenic morbidity are numerous. They range from community surveys and studies of pedigrees to case-control designs for assessment of risk factors and long-term followup investigations of course and outcome. This review focuses on epidemiological approaches to schizophrenia that have attempted to highlight the essential attributes of a disease: its incidence and prevalence, ecology, and associated features. It is difficult to generalize about European epidemiological research in schizophrenia, because of the coexistence of a variety of "schools," traditions, and approaches. It is nevertheless possible to discern several clear trends in European epidemiological investigations of schizophrenia that can, to some extent, be contrasted to North American developments.

Entities:  

Mesh:

Year:  1986        PMID: 3961427     DOI: 10.1093/schbul/12.1.52

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  9 in total

1.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

2.  Social outcome in schizophrenia: a 13-year follow-up.

Authors:  P Munk-Jørgensen; P B Mortensen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-05       Impact factor: 4.328

Review 3.  Antipsychotic medication for elderly people with schizophrenia.

Authors:  R G Marriott; W Neil; S Waddingham
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  Political dissent and "sluggish" schizophrenia in the Soviet Union.

Authors:  G Wilkinson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

5.  Some aspects of the cost of schizophrenia in France.

Authors:  F Rouillon; M Toumi; G Y Dansette; J Benyaya; P Auquier
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 6.  What is schizophrenia? Changing perspectives in epidemiology.

Authors:  H Häfner
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

Review 7.  Season of birth in amyotrophic lateral sclerosis.

Authors:  V Ajdacic-Gross; J Wang; F Gutzwiller
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

Review 8.  Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

Authors:  Daniel W Bradford; Diana O Perkins; Jeffrey A Lieberman
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.

Authors:  Christophe Lançon; Mondher Toumi; Christophe Sapin; Karina Hansen
Journal:  BMC Psychiatry       Date:  2008-07-18       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.